Table 5 Treatment duration by drug
Treatment Pattern | |
|---|---|
Patients switched from first-line treatment, n | 182 |
Duration of the first-line treatment, months (mean ± SD) | |
Fixed combination | 8.19 ± 8.98 |
Unfixed combination | 16.94 ± 18.05 |
Duration of first-line treatment, months (mean ± SD) | |
PGA | 12.63 ± 14.88 |
BB | 13.9 ± 16.79 |
CAI | 5.14 ± 7.20 |
α-blocker | 6.71 ± 5.91 |
α-agonist | 4.36 ± 6.54 |
Others | 17 ± 22.28 |
PGA/BB | 8.47 ± 9.39 |
CAI/BB | 5.2 ± 6.83 |
Of those switched to fixed combination as second-line, n (%) | n = 104 |
Switched to another drug in the third-line | 22 (21.15) |
Added on another drug in the third-line | 18 (17.31) |
Dropped the combination therapy | 25 (24.04) |
Stayed on the combination therapy | 39 (37.50) |
Of those switched to unfixed combination as second-line, n (%) | n = 78 |
Switched to another drug in the third-line | 16 (20.51) |
Added on another drug in the third-line | 15 (19.23) |
Dropped the combination therapy | 21 (26.92) |
Stayed on the combination therapy | 26 (33.33) |
Duration of second-line treatment (added on in the third-line), months (mean ± SD) | |
PGA | 8.08 ± 4.37 |
BB | 7.02 ± 4.55 |
CAI | 6.52 ± 4.94 |
α-blocker | 7.00 ± 5.77 |
α-agonist | 5.58 ± 4.60 |
Others | 4.86 ± 3.63 |
PGA/BB | 6.90 ± 4.61 |
CAI/BB | 7.03 ± 4.46 |
Duration of second-line treatment (switched in the third-line), month (mean ± SD) | |
PGA | 7.08 ± 4.54 |
BB | 7.39 ± 4.38 |
CAI | 4.40 ± 2.88 |
α-blocker | 10.00 ± 2.00 |
α-agonist | 7.00 ± 7.07 |
Othersa | 4.75 ± 4.86 |
PGA/BB | 7.14 ± 4.64 |
CAI/BB | 2.92 ± 2.78 |